The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $674,726 in first-year total cost, median $224,998.
Most frequent study sections
- Special Emphasis Panel[ZHD1 DSR-K (52)]3
Most frequent institutions
- EPPIN PHARMA, INC.1
- MUCOMMUNE, LLC1
- YOURCHOICE THERAPEUTICS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Drug Interactions in vitro for EP055: a Non-Hormonal Male Contraceptive1R43HD097820-01 | ORAND, MICHAEL GENE | EPPIN PHARMA, INC., NC | $225,000 | ZHD1 |
| 2019 | Plant-derived molecular condom as an on-demand nonhormonal female contraceptive1R43HD097944-01 | MANNOWETZ, NADJA | YOURCHOICE THERAPEUTICS, INC., CA | $224,998 | ZHD1 |
| 2019 | Non-hormonal contraception based on vaginal delivery of multimeric sperm-binding antibodies1R43HD097941-01 | CONE, RICHARD | MUCOMMUNE, LLC, NC | $224,728 | ZHD1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.